Literature DB >> 8239596

Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.

J A Hobden1, J M Hill, L S Engel, R J O'Callaghan.   

Abstract

This study was conducted to determine whether the age of the host influences the pathogenesis and therapeutic outcome of drug-treated Pseudomonas aeruginosa keratitis. Young (3- to 5-month-old) and old (1.5- to 3-year-old) rabbits were intrastromally infected with P. aeruginosa ATCC 27853. Sixteen hours later, rabbits in both age subpopulations were divided into three groups and treated topically as follows: group 1, phosphate-buffered saline; group 2, 0.3% ciprofloxacin; and group 3, 0.3% ciprofloxacin, 1.0% prednisolone, and 0.03% flurbiprofen. Drops were given every 15 min for 1 h and then every 30 min for 9 h. At 27 h postinfection, ocular pathology was graded with a slit lamp examination (SLE) scoring system. Aqueous humor was collected for ciprofloxacin quantitation, and corneas were harvested for bacterial enumeration and estimation of polymorphonuclear leukocytes. Young rabbits had more severe inflammation and pathology than old rabbits. At 27 h postinfection, SLE scores and polymorphonuclear leukocyte numbers were significantly higher for young rabbits than old rabbits (P < 0.02), regardless of treatment. Prednisolone and flurbiprofen significantly reduced SLE scores in both age groups (P < 0.03) without affecting the antimicrobial efficacy of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239596      PMCID: PMC188082          DOI: 10.1128/AAC.37.9.1856

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Fulminant pseudomonal keratitis and scleritis in human immunodeficiency virus-infected patients.

Authors:  M Nanda; S C Pflugfelder; S Holland
Journal:  Arch Ophthalmol       Date:  1991-04

Review 2.  Altered immune status in the elderly.

Authors:  R J Simons; H Y Reynolds
Journal:  Semin Respir Infect       Date:  1990-12

3.  Rabbit corneal damage produced by Pseudomonas aeruginosa infection.

Authors:  L D Gray; A S Kreger
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

4.  Atypical presentation of geriatric infections.

Authors:  R A Fox
Journal:  Geriatrics       Date:  1988-05

5.  Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis.

Authors:  J A Hobden; J J Reidy; R J O'Callaghan; M S Insler; J M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-10       Impact factor: 4.799

6.  Cleavage and activation of corneal matrix metalloproteases by Pseudomonas aeruginosa proteases.

Authors:  K Matsumoto; N B Shams; L A Hanninen; K R Kenyon
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-05       Impact factor: 4.799

7.  Aging alters the phagocytic capability of inflammatory cells induced into cornea.

Authors:  L D Hazlett; F B Kreindler; R S Berk; R Barrett
Journal:  Curr Eye Res       Date:  1990-02       Impact factor: 2.424

8.  Relevance of host-derived and bacterial factors in Pseudomonas aeruginosa corneal infections.

Authors:  K P Steuhl; G Döring; A Henni; H J Thiel; K Botzenhart
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-09       Impact factor: 4.799

9.  Topical anti-inflammatory agents in an animal model of microbial keratitis.

Authors:  D C Gritz; T Y Lee; S Kwitko; P J McDonnell
Journal:  Arch Ophthalmol       Date:  1990-07

10.  Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit.

Authors:  D S Rootman; J A Hobden; J A Jantzen; J R Gonzalez; R J O'Callaghan; J M Hill
Journal:  Arch Ophthalmol       Date:  1988-02
View more
  8 in total

1.  Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

2.  The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Zachary M Robertson; Quincy C Moore; Jonathan Fratkin; Mary E Marquart
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-22       Impact factor: 4.799

Review 3.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis.

Authors:  Melissa E Sanders; Nathan A Tullos; Sidney D Taylor; Erin W Norcross; Lauren B King; Isaiah Tolo; Mary E Marquart
Journal:  Curr Eye Res       Date:  2010-12       Impact factor: 2.424

5.  Corneal cross-linking guards against infectious keratitis: an experimental model.

Authors:  Ayah Marrie; Abdussalam M Abdullatif; Sherief Gamal El Dine; Rania Yehia; Randa Saied; Doaa Ahmed Tolba
Journal:  Int Ophthalmol       Date:  2022-10-18       Impact factor: 2.029

6.  Changing trends in the clinical course and outcome of bacterial keratitis at King Khaled Eye Specialist Hospital.

Authors:  Ali Al-Shehri; Sabah Jastaneiah; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2008-04-03       Impact factor: 2.031

7.  Passive immunization with Pneumovax® 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis.

Authors:  Melissa E Sanders; Sidney Taylor; Nathan Tullos; Erin W Norcross; Quincy C Moore; Hilary Thompson; Lauren B King; Mary E Marquart
Journal:  BMC Ophthalmol       Date:  2013-03-11       Impact factor: 2.209

8.  Infectious keratitis: secreted bacterial proteins that mediate corneal damage.

Authors:  Mary E Marquart; Richard J O'Callaghan
Journal:  J Ophthalmol       Date:  2013-01-08       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.